{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Predictors of clinical outcomes will be investigated using logistic regression, Cox proportional hazards regression and/or generalized estimating equations as appropriate. Descriptive statistics and plotting of data will be used to better understand potential relationships.","groups":[{"description":"Patients receive WEE1 inhibitor MK-1775 PO BID for 5 doses beginning on day 1 and cisplatin IV over 1 hour on day 1.\n\nCisplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nWEE1 Inhibitor AZD1775: Given PO","id":"OG000","title":"Arm I (WEE1 Inhibitor MK-1775, Cisplatin)"},{"description":"Patients receive placebo PO BID for 5 doses beginning on day 1 and cisplatin IV over 2 hour on day 1.\n\nCisplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nPlacebo: Given PO","id":"OG001","title":"Arm II (Placebo, Cisplatin)"}],"populationDescription":"No data are available as decision was made by PI not to do the analysis due to small number of patients","reportingStatus":"POSTED","timeFrame":"Pre-dose, at 4-8 hours on day 3 or 20-24 hours on day 4","title":"Levels of Pharmacodynamic Biomarkers","type":"SECONDARY"}